Mode
Text Size
Log in / Sign up

Neuromyelitis Optica

Part of Demyelinating Autoimmune Diseases, CNS

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neuromyelitis Optica

10 trials tracked for Neuromyelitis Optica: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 78 citations.

10Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 4 Phase 1 3 Other / NA 1
  1. Phase 3 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Completed · 78 cited
  2. Phase 3 An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Completed · 8 cited
  3. Phase 2 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed
  4. Phase 2 Neuromyelitis Optica (NMO) & Cetirizine Completed
  5. Phase 2 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed
  6. Phase 2 High Frequency Impulse Therapy for Neuropathic Pain in NMOSD Completed
Show 4 more trials
  1. Phase 1 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed
  2. Phase 1 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Completed
  3. Phase 1 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed
  4. N/A Scrambler Trial for Pain in NMOSD Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Demyelinating Autoimmune Diseases, CNS

Related studies from across the Demyelinating Autoimmune Diseases, CNS family.

Case report and literature review of severe adverse reactions following pucotenlimab treatment
Allergy & Immunology Sys. Review
Case report and literature review of severe adverse reactions following pucotenlimab treatment New drug treatment linked to severe neurological reactions
This case report and literature review describes severe adverse reactions following treatment with pucotenlimab in a patient with advanced b…
A single patient facing advanced breast cancer experienced life-threatening neurological symptoms after receiving the drug pucotenlimab.
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes
Oncology Cohort
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
Narrative review of animal models in neuromyelitis optica spectrum disorder pathogenesis
Rheumatology Sys. Review
Narrative review of animal models in neuromyelitis optica spectrum disorder pathogenesis Animal Models Are Unlocking New Treatments for Rare Brain Disease
This narrative review examines animal models used to study neuromyelitis optica spectrum disorder pathogenesis.
Better animal models are helping scientists understand how NMOSD damages the brain, offering hope for new treatments for patients with few o…
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients
Allergy & Immunology Phase II
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients A New MS-Like Disease Drug Passes Its First Human Safety Test
This Phase 1b randomized, double-blind, placebo-controlled trial evaluated intravenous B001 in 22 patients with aquaporin-4 immunoglobulin G…
A new drug for a rare nerve disease that can cause blindness and paralysis passed its first human safety test with no severe side effects se…